Curi Bio and NEXEL Announce Celogics, a Joint Venture to Develop Leading Cellular Products Derived from iPSC



SEATTLE & SEOUL, South Korea – (COMMERCIAL THREAD) – Curi Bio, a global leader in the development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, announced today the formation of Celogics, a joint venture company focused on the development and commercialization of human cellular products derived from iPSC for drug discovery, drug safety testing and biological research. Celogics iPSC’s production and distribution headquarters will be located in Seattle, WA.

The United States represents nearly 50% of the global stem cell market, and Celogics’ joint venture partnership with market leader Curi Bio will represent a major strategic entry for Nexel into the United States. Celogics will supply Nexel’s iPSC-derived cellular products, including Cardiosight®-S cardiomyocytes, to the U.S. and global markets, and launch a Seattle-based iPSC production facility to support rapid growth and development services and manufacturing iPSC contracts. Celogics will also develop and market next generation iPSC-derived cellular products.

Curi Bio is a world leader in the development of cardiac, skeletal and neuromuscular muscles in vitro disease models and provides leading-edge products and services for human tissue modeling for drug discovery. Curi’s 3D tissue engineering platform (Mantarray â„¢) can be used in combination with cell models derived from iPSC to develop advanced 3D models of heart and muscle tissue for phenotypic screening. Curi Bio has already received over $ 7 million in grants from the U.S. National Institutes of Health to support the development of core technologies, including a proprietary approach for advanced functional maturation of iPSC-derived cardiomyocytes (ComboMat â„¢ ). By providing the world’s leading pharmaceutical companies with access to models relevant to humans during preclinical drug development, Curi Bio helps leading pharmaceutical companies develop safer and more effective treatments in less time and at lower cost. NEXEL was the first Korean company to license iPSC technology and advanced the in vitro area of ​​toxicity through the successful commercialization of iPSC-derived cells that better mimic human cell function.

Human cells derived from iPSC are rapidly becoming an essential tool in the drug development industry for the discovery, preclinical efficacy testing and safety profiling of new drugs. IPSCs can be differentiated into a wide variety of human cell types including cardiomyocytes, neurons, hepatocytes and many others, and can be created from healthy individuals or patients with specific diseases through a process called cell reprogramming. The iPSC-derived disease models serve as platforms for the discovery of next-generation therapies.

Pharmaceutical industry researchers are increasingly relying on gene editing technologies such as CRISPR to create genetically engineered iPSC-derived cell models of human diseases, including cardiomyopathies and muscular dystrophies. Following significant collaborative initiatives between US regulators and companies in the iPSC industry, human cardiomyocytes derived from iPSCs are increasingly used by the world’s leading pharmaceutical companies for screening for cardiac safety.

“As a joint venture partnership between Curi Bio and Nexel, Celogics will be uniquely positioned to meet the large and rapidly growing need for high quality iPSC-derived human cell products,” said Michael Cho, CEO of Curi Bio. “We look forward to helping leading researchers and pharmaceutical companies accelerate the discovery and development of next-generation therapies. ”

“Celogics is the global market leader in somatic cell products derived from stem cells for toxicity assessment and drug discovery,” said Choong-seong Han, CEO of Nexel. “We are committed to developing and producing exceptional iPSCs that pharmaceutical quality control standards demand.

About Curi Bio

Curi Bio’s preclinical discovery platform combines human stem cells, systems and data to accelerate the discovery of new drugs. The Curi Engine is a seamless bioengineering platform that integrates human cell models derived from iPSC, tissue-specific biosystems, and AI / ML-based phenotypic screening data. Curi’s suite of human stem cell products and services enable scientists to create more mature and predictive iPSC-derived human tissues, with a focus on cardiac, musculoskeletal and neuromuscular models, for the discovery, safety testing and efficacy testing of new drugs. in development. By providing drug developers with an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically relevant data, Curi bridges the gap between preclinical data and human outcomes, accelerating drug discovery and development. safer and more efficient.

For more information, please visit


NEXEL, Co., Ltd. is a bio-company that was incorporated in 2012 with exclusive stem cell technologies. Their philosophy is to “make a better place” by supporting innovative research around the world by providing high quality cell products derived from stem cells. NEXEL, Co., Ltd. launched Cardiosight®-S in 2018, which has since been validated on multiple platforms as a pure and functional population of hiPSC-derived cardiomyocytes. Other product lines include Hepatosight®-S (iPS-derived hepatocytes) and Neurosight®-S (iPS-derived neurons).

For more information, please visit:



Leave A Reply